However, our recent knowledge on the genetics of cutaneous melanoma is far more complex and identified actionable gene defects such as NRAS, KIT or IDH1 mutations and NRAS mutant melanoma are now in clinical trials. This evidence concerns the gene NRAS and melanoma.